Venetoclax added to standard treatments shows promise in high-risk myeloid blood cancers ...Middle East

- News
Venetoclax added to standard treatments shows promise in high-risk myeloid blood cancers
The novel oral drug venetoclax can be safely added to standard therapies for some high-risk myeloid blood cancers and in early studies the combination shows promise of improved outcomes, say scientists from Dana-Farber Cancer Institute.

Hence then, the article about venetoclax added to standard treatments shows promise in high risk myeloid blood cancers was published today ( ) and is available on ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Venetoclax added to standard treatments shows promise in high-risk myeloid blood cancers )

Apple Storegoogle play

Last updated :

Also on site :